MX2017006813A - Composicion farmaceutica, preparacion y usos de la misma. - Google Patents

Composicion farmaceutica, preparacion y usos de la misma.

Info

Publication number
MX2017006813A
MX2017006813A MX2017006813A MX2017006813A MX2017006813A MX 2017006813 A MX2017006813 A MX 2017006813A MX 2017006813 A MX2017006813 A MX 2017006813A MX 2017006813 A MX2017006813 A MX 2017006813A MX 2017006813 A MX2017006813 A MX 2017006813A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compound
nanoparticle
subject
pharmaceutical composition
preparation
Prior art date
Application number
MX2017006813A
Other languages
English (en)
Inventor
Levy Laurent
Meyre Marie-Edith
Pottier Agnès
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of MX2017006813A publication Critical patent/MX2017006813A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende la combinación de (i) al menos una nanopartícula biocompatible y de (ii) al menos un compuesto farmacéutico, para administrarse a un sujeto que necesite dicho compuesto farmacéutico, en donde las nanopartículas potencian la eficacia del compuesto farmacéutico. La dimensión más larga de la nanopartícula biocompatible es típicamente entre aproximadamente 4 y aproximadamente 500 nm, su valor absoluto de carga superficial es de al menos 10 mV (|10 mV|), y su módulo de Young es menor que 100 kPa. La invención también se refiere a dicha composición para usarse para administrar el compuesto farmacéutico en un sujeto que lo necesite, en el que la al menos una nanopartícula y el al menos un compuesto farmacéutico se administren en el sujeto entre más de 5 minutos y aproximadamente 72 horas uno del otro.
MX2017006813A 2014-11-25 2015-11-24 Composicion farmaceutica, preparacion y usos de la misma. MX2017006813A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306873 2014-11-25
PCT/EP2015/077438 WO2016083336A1 (en) 2014-11-25 2015-11-24 Pharmaceutical composition, preparation and uses thereof

Publications (1)

Publication Number Publication Date
MX2017006813A true MX2017006813A (es) 2018-01-30

Family

ID=52013980

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006813A MX2017006813A (es) 2014-11-25 2015-11-24 Composicion farmaceutica, preparacion y usos de la misma.

Country Status (16)

Country Link
US (1) US20170258718A1 (es)
EP (1) EP3229781A1 (es)
JP (1) JP2018500298A (es)
KR (1) KR20170086638A (es)
CN (1) CN107106505A (es)
AR (1) AR102779A1 (es)
AU (1) AU2015352688A1 (es)
BR (1) BR112017010933A2 (es)
CA (1) CA2968473A1 (es)
EA (1) EA201791138A1 (es)
HK (1) HK1245086A1 (es)
IL (1) IL252397A0 (es)
MX (1) MX2017006813A (es)
SG (1) SG11201704143YA (es)
TW (1) TW201628639A (es)
WO (1) WO2016083336A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014273043B2 (en) 2013-05-30 2019-02-07 Curadigm Sas Pharmaceutical composition, preparation and uses thereof
DK3223796T3 (da) 2014-11-25 2021-09-27 Curadigm Sas Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
PT3229843T (pt) 2014-11-25 2020-03-06 Curadigm Sas Composição farmacêutica, a sua preparação e as suas utilizações
PT3236934T (pt) 2014-11-25 2024-08-01 Curadigm Sas Composição farmacêutica, preparação e suas utilizações
PT3229776T (pt) 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
CN107708668A (zh) 2015-05-28 2018-02-16 纳米生物技术公司 用作治疗性疫苗的纳米粒子
CN111886004A (zh) * 2017-12-19 2020-11-03 纳米生物技术公司 用于治疗神经元障碍的纳米粒子

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2547024C (en) 2003-12-22 2013-12-17 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
US20080193372A1 (en) * 2004-02-10 2008-08-14 Barnes-Jewish Hospital Efficacy and Safety of Targeted Particulate Agents with Decoy Systems
WO2007122956A1 (ja) * 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
EP1852107A1 (en) 2006-04-19 2007-11-07 Nanobiotix Magnetic nanoparticles compositions and uses thereof
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
PL2670394T3 (pl) * 2011-01-31 2019-03-29 Nanobiotix Układy do dostarczania nanocząstek, ich otrzymywanie i zastosowania
EP2670393B8 (en) * 2011-01-31 2016-10-05 Nanobiotix Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles.
ITRM20120480A1 (it) * 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.

Also Published As

Publication number Publication date
SG11201704143YA (en) 2017-06-29
TW201628639A (zh) 2016-08-16
EA201791138A1 (ru) 2017-09-29
CN107106505A (zh) 2017-08-29
CA2968473A1 (en) 2016-06-02
IL252397A0 (en) 2017-07-31
HK1245086A1 (zh) 2018-08-24
KR20170086638A (ko) 2017-07-26
EP3229781A1 (en) 2017-10-18
US20170258718A1 (en) 2017-09-14
AU2015352688A1 (en) 2017-07-13
BR112017010933A2 (pt) 2018-02-14
WO2016083336A1 (en) 2016-06-02
JP2018500298A (ja) 2018-01-11
AR102779A1 (es) 2017-03-22

Similar Documents

Publication Publication Date Title
NZ714273A (en) Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof
MX2017006813A (es) Composicion farmaceutica, preparacion y usos de la misma.
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
MX2021010595A (es) Composicion farmaceutica, preparacion y usos de la misma.
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
EP3904502A3 (en) Compositions and methods
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
MX355065B (es) Método y dispositivo para conmutación de cámaras.
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
MX2016005668A (es) Formas cristalinas de compuestos terapeuticos y sus usos.
AR092993A1 (es) Laquinimod para reducir el daño talamico en la esclerosis multiple
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
SG10201907291QA (en) Monomethylfumarate prodrug compositions
PH12015502747A1 (en) Novel compounds for the treatment of cancer
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
MX2017009929A (es) Composiciones y métodos para metabolismo muscular mejorado.
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
PH12015502727A1 (en) Methods and compositions for enhancing cognitive performance
TR201905694T4 (tr) Aripiprazol ön ilaç bileşimleri.